A CD1d-dependent lipid antagonist to NKT cells ameliorates atherosclerosis in ApoE-/- mice by reducing lesion necrosis and inflammation

Cardiovascular Research

Volumn 109, Issue 2, 2016, Pages 305-317

  Li, Yi ^a,b   Kanellakis, Peter ^a   Hosseini, Hamid ^a,b   Cao, Anh ^a,b   Deswaerte, Virginie ^a,c   Tipping, Peter ^b   Toh, Ban Hock ^b   Bobik, Alex ^a,d   Kyaw, Tin ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b Southern Clinical School   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

ApoE mice; Atherosclerosis; DPPE PEG; NKT antagonist; NKT cells

Indexed keywords

1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N[METHOXY(POLYETHYLENE GLYCOL) 350]; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CD19 ANTIGEN; CD1D ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; COLLAGEN; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CD1D ANTIGEN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EXPERIMENTAL ATHEROSCLEROSIS; GENE EXPRESSION; HYPERLIPIDEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; LIPID BLOOD LEVEL; MALE; MOUSE; NATURAL KILLER T CELL; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ATHEROSCLEROTIC PLAQUE; CYTOLOGY; DEFICIENCY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD1D; APOLIPOPROTEINS E; ATHEROSCLEROSIS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; NECROSIS; PLAQUE, ATHEROSCLEROTIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84959898842     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv259     Document Type: Article

References (58)

1. Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, Toh BH. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 2013;127: 1028-1039.
2. Hayes EM, Tsaousi A, Di Gregoli K, Jenkinson SR, Bond AR, Johnson JL, Bevan L, Thomas AC, Newby AC. Classical and alternative activation and metalloproteinase expression occurs in foam cell macrophages in male and female ApoE null mice in the absence of T and B lymphocytes. Front Immunol 2014;5:537.
3. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-1292.
4. van derWal AC, Becker AE. Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability. Cardiovasc Res 1999;41:334-344.
5. Pellicori P, Costanzo P, Joseph AC, Hoye A, Atkin SL, Cleland JG. Medical management of stable coronary atherosclerosis. Curr Atheroscler Rep 2013;15:313.
6. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002;56:53-56.
7. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-2138.
8. Niessner A, Goronzy JJ, Weyand CM. Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations. Curr Pharm Des 2007;13: 3701-3710.
9. Nilsson J, Wigren M, Shah PK. Vaccines against atherosclerosis. Expert Rev Vaccines 2013;12:311-321.
10. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vre E, Esposito B, Vilar J, Sirvent J, Van Snick J, Tedgui A, Tedder TF, Mallat Z. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010;207: 1579-1587.
11. Kyaw T, Cui P, Tay C, Kanellakis P, Hosseini H, Liu E, Rolink AG, Tipping P, Bobik A, Toh BH. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(2/2) mice. PLoS ONE 2013;8:e60430.
12. Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, Kehry M, Dunn R, Agrotis A, Tipping P, Bobik A, Toh BH. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010;185:4410-4419.
13. Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, Loinard C, Binder CJ, Mallat Z. BAFF receptor deficiency reduces the development of atherosclerosis in mice-brief report. Arterioscler Thromb Vasc Biol 2012;32:1573-1576.
14. Dinh TN, Kyaw TS, Kanellakis P, To K, Tipping P, Toh BH, Bobik A, Agrotis A. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation 2012;126:1256-1266.
15. Wigren M, Kolbus D, Duner P, Ljungcrantz I, Soderberg I, Bjorkbacka H, Fredrikson GN, Nilsson J. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med 2011;269: 546-556.
16. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25: 297-336.
17. Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, OFarrelly C, Doherty DG. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 2003;171:1775-1779.
18. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-1388.
19. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.
20. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, Mallevaey T, Clarke AJ, Le Nours J, Theodossis A, Cardell SL, Gapin L, Godfrey DI, Rossjohn J. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol 2012;13:857-863.
21. Chan WL, Pejnovic N, Hamilton H, Liew TV, Popadic D, Poggi A, Khan SM. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ Res 2005;96:675-683.
22. Kyriakakis E, Cavallari M, Andert J, Philippova M, Koella C, Bochkov V, Erne P, Wilson SB, Mori L, Biedermann BC, Resink TJ, De Libero G. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur J Immunol 2010;40:3268-3279.
23. To K, Agrotis A, Besra G, Bobik A, Toh BH. NKT cell subsets mediate differential proatherogenic effects in ApoE2/2 mice. Arterioscler Thromb Vasc Biol 2009;29: 671-677.
24. Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, Onoe K. Natural killer T cells accelerate atherogenesis in mice. Blood 2004;104:2051-2059.
25. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004;199:417-422.
26. Rogers L, Burchat S, Gage J, Hasu M, Thabet M, Willcox L, Ramsamy TA, Whitman SC. Deficiency of invariant V alpha 14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. Cardiovasc Res 2008;78:167-174.
27. VanderLaan PA, Reardon CA, Sagiv Y, Blachowicz L, Lukens J, Nissenbaum M, Wang CR, Getz GS. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol 2007;170:1100-1107.
28. Li Y, To K, Kanellakis P, Hosseini H, Deswaerte V, Tipping P, Smyth MJ, Toh BH, Bobik A, Kyaw T. CD4+ natural killer T cells potently augment aortic root atherosclerosis by perforin-And granzyme B-dependent cytotoxicity. Circ Res 2015;116:245-254.
29. Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, Li X, Shiratsuchi T, Hnatiuk NE, Howell AR, Yu KO, Porcelli SA, Tsuji M, Kronenberg M, Wilson SB, Akbari O. A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol 2010; 184:2107-2115.
30. Nieuwenhuis EE, Gillessen S, Scheper RJ, Exley MA, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Blumberg RS, Wilson SB. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol 2005;14:250-258.
31. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM. A phase I study of the natural killer T-cell ligand alphagalactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8: 3702-3709.
32. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2: 123-128.
33. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR22/2 mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394: 894-897.
34. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-1262.
35. Silber A, NewmanW, Sasseville VG, Pauley D, Beall D, Walsh DG, Ringler DJ. Recruitment of lymphocytes during cutaneous delayed hypersensitivity in nonhuman primates is dependent on E-selectin and vascular cell adhesion molecule 1. J Clin Invest 1994;93: 1554-1563.
36. MartinetW, Schrijvers DM, De Meyer GR. Necrotic cell death in atherosclerosis. Basic Res Cardiol 2011;106:749-760.
37. Jin XH, Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-Acyltransferase generating the anandamide precursor and its congeners. J Biol Chem 2007;282:3614-3623.
38. Gillum MP, Zhang D, Zhang XM, Erion DM, Jamison RA, Choi C, Dong J, Shanabrough M, Duenas HR, Frederick DW, Hsiao JJ, Horvath TL, Lo CM, Tso P, ClineGW, Shulman GI. N-Acylphosphatidylethanolamine, a gut-derived circulating factor induced by fat ingestion, inhibits food intake. Cell 2008;135:813-824.
39. Tonti E, Galli G, Malzone C, Abrignani S, Casorati G, Dellabona P. NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood 2009;113: 370-376.
40. Hodge DL, Reynolds D, Cerban FM, Correa SG, Baez NS, Young HA, Rodriguez-Galan MC. MCP-1/CCR2 interactions direct migration of peripheral B and T lymphocytes to the thymus during acute infectious/inflammatory processes. Eur J Immunol 2012;42:2644-2654.
41. Damle NK, Aruffo A. Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+ T lymphocytes. Proc Natl Acad Sci USA 1991;88:6403-6407.
42. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773-778.
43. Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J Clin Invest 2011;121:249-264.
44. Kavurma MM, Bhindi R, Lowe HC, Chesterman C, Khachigian LM. Vessel wall apoptosis and atherosclerotic plaque instability. J Thromb Haemost 2005;3:465-472.
45. Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res 2009;50(Suppl):S382-S387.
46. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, WisslerRW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355-1374.
47. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:1256-1261.
48. Kono H, Kimura Y, Latz E. Inflammasome activation in response to dead cells and their metabolites. Curr Opin Immunol 2014;30:91-98.
49. Clarke MC, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res 2010;106:363-372.
50. Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and inflammation: An auto-Amplification loop causes organ failure. Nat Rev Immunol 2014;14: 759-767.
51. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010;2010, doi: 10.1155/2010/672395.
52. Zheng Y, Gardner SE, Clarke MC. Cell death, damage-Associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 2011; 31:2781-2786.
53. Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, Takahashi HK, Liu K, Peter K, Nishibori M, Bobik A. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011;31:313-319.
54. Kockx MM, De Meyer GR, Muhring J, JacobW, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998;97: 2307-2315.
55. Loffredo S, Staiano RI, Granata F, Costantino V, Borriello F, Frattini A, Lepore MT, Mangoni A, Marone G, Triggiani M. Simplexide induces CD1d-dependent cytokine and chemokine production from human monocytes. PLoS ONE 2014;9:e111326.
56. Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S, Keating R, Kronenberg M, Smyth MJ, Godfrey DI. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003;171:4020-4027.
57. Melian A, Geng YJ, Sukhova GK, Libby P, Porcelli SA. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am J Pathol 1999; 155:775-786.
58. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: An innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013;13:101-117.